{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-001558","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.718702+00:00","generated_at":"2026-06-07T19:16:30.753523+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lipella believes it meets Nasdaq minimum equity rule after $2M private placement","bullets":["Private placement closed Oct 25, 2023; gross proceeds $2.0M, net ~$1.7M.","Stockholders' equity as-adjusted: ~$3.9M (Sep 30, 2023) and ~$3.8M (Oct 31, 2023), above $2.5M minimum.","Nasdaq will continue to monitor ongoing compliance; no assurance of future compliance.","Previously disclosed Nasdaq delinquency notice on Nov 21, 2023 for minimum equity rule.","Pre-funded warrants issued at $1.519/unit; exercise $0.001 per share; common warrants $1.40, 3-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-001558","json":"https://secwatch.observer/filing/0001753926-23-001558.json","markdown":"https://secwatch.observer/filing/0001753926-23-001558.md","text":"https://secwatch.observer/filing/0001753926-23-001558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623001558/0001753926-23-001558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392623001558/g083874_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:16:30.753523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}